Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 10, 2003, Pages 3339-3342

  Risovic, Verica ^a   Boyd, Michael ^a   Choo, Eugene ^a   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; BUFFER; CREATININE; DEOXYCHOLATE SODIUM; DEOXYCHOLIC ACID; INTRALIPID; LIPID; PHOSPHATE; SODIUM DIHYDROGEN PHOSPHATE; TRIACYLGLYCEROL;

ANIMAL; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IATROGENIC DISEASE; KIDNEY DISEASE; MALE; MICELLE; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RAT STRAIN; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CREATININE; DEOXYCHOLIC ACID; DRUG DELIVERY SYSTEMS; KIDNEY DISEASES; LIPIDS; MALE; MICELLES; PHOSPHATES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; TRIGLYCERIDES;

EID: 0141890238     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.10.3339-3342.2003     Document Type: Article

References (23)

1. Blom, G. 1958. Statistical estimates and transformed beta variables, p. 1-58. John Wiley and Sons, Inc., New York, N.Y.
2. Chavanet, P., V. Joly, D. Rigaud, J. Bolard, C. Carbon, and P. Yeni. 1994. Influence of diet on experimental toxicity of amphotericin B deoxycholate. Antimicrob. Agents Chemother. 38:963-968.
3. Dangi, J. S., S. P. Vyas, and V. K. Dixit. 1998. Effects of various lipid-bile salt mixed micelles on the intestinal absorption of amphotericin-B in rat. Drug Dev. Ind. Pharm. 24:631-635.
4. Egito, E. S. T., I. B. Araujo, P. G. Bolivar, L. Damasceno, and J. C. Price. 2002. Amphotericin B/emulsion admixture interactions: an approach concerning the reduction of amphotericin B toxicity. J. Pharm. Sci. 91:2354-2366.
5. Fagerholm, U., M. Johansson, and H. Lennernas. 1996. Comparison between permeability coefficients in rat and human jejunum. Pharm. Res. 13:1336-1342.
6. Gates, C., and R. J. Pinney. 1993. Amphotericin B and its delivery by liposomal and lipid formulations. J. Clin. Pharm. Ther. 18:147-153.
7. Hauss, D. J., S. E. Fogal, J. V. Ficorilli, C. A. Price, T. Roy, A. A. Jayaraj, and J. J. Kerns. 1998. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J. Pharm. Sci. 87:164-169.
8. Holm, R., C. J. Porter, A. Mullertz, H. G. Kristensen, and W. N. Charman. 2002. Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats. Pharm. Res. 19:1354-1361.
9. Kararli, T. T. 1995. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm. Drug Dispos. 16:351-380.
10. Lance, M. R., C. Washington, and S. S. Davis. 1995. Structure and toxicity of amphotericin B/triglyceride emulsion formulations. J. Antimicrob. Chemother. 36:119-128.
11. Levet-Trafit, B., M. S. Gruyer, M. Marjanovic, and R. C. Chou. 1996. Estimation of oral drug absorption in man based on intestine permeability in rats. Life Sci. 58:PL359-PL363.
12. Manfredi, R., and F. Chiodo. 1998. Case-control study of amphotericin B in a triglyceride fat emulsion versus conventional amphotericin B in patients with AIDS. Pharmacotherapy 18:1087-1092.
13. Meyer, R. D. 1992. Current role of therapy with amphotericin B. Clin. Infect. Dis. 14:S154-S160.
14. Porter, C. J., and W. N. Charman. 2001. Intestinal lymphatic drug transport: an update. Adv. Drug Delivery Rev. 50:61-80.
15. Reymond, J. P., H. Sucker, and J. Vonderscher. 1988. In vivo model for ciclosporin intestinal absorption in lipid vehicles. Pharm. Res. 5:677-679.
16. Soria, I., and C. L. Zimmerman. 1996. The validation of the intestinal permeability approach to predict oral fraction of dose absorbed in humans and rats. Biopharm. Drug Dispos. 17:817-818.
17. Souza, L. C., R. C. Maranhao, S. Schreier, and A. Campa. 1993. In-vitro and in-vivo studies of the decrease of amphotericin B toxicity upon association with a triglyceride-rich emulsion. J. Antimicrob. Chemother. 32:123-132.
18. Souza, L. C., and A. Campa. 1999. Pharmacological parameters of intravenously administered amphotericin B in rats: comparison of the conventional formulation with amphotericin B associated with a triglyceride-rich emulsion. J. Antimicrob. Chemother. 44:77-84.
19. Souza, L. C., P. H. Saldiva, and A. Campa. 2000. Lipid emulsion reduces subacute toxicity of amphotericin B: a histopathological study. Exp. Toxicol. Pathol. 52:169-175.
20. Wasan, K. M., K. Vadici, G. Lopez-Berestein, and D. R. Luke. 1990. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J. Infect. Dis. 161:562-566.
21. Wasan, K. M., V. B. Grossie, Jr., and G. Lopez-Berestein. 1994. Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous Intralipid infusion. Antimicrob. Agents Chemother. 38:2224-2226.
22. Wasan, K. M., A. L. Kennedy, S. M. Cassidy, M. Ramaswamy, L. Holtorf, J. W.-L. Chou, and P. H. Pritchard. 1998. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Antimicrob. Agents Chemother. 42:3146-3152.
23. Wasan, K. M. 2002. The role of lymphatic transport in enhancing oral protein and peptide drug delivery. Drug Dev. Ind. Pharm. 28:1047-1058.